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Abstract
Background
The role of urate in cardiovascular diseases (CVDs) has been extensively investigated in
observational studies; however, the extent of any causal effect remains unclear, making it
difficult to evaluate its clinical relevance.
Methods and findings
A phenome-wide association study (PheWAS) together with a Bayesian analysis of tree-
structured phenotypic model (TreeWAS) was performed to examine disease outcomes
related to genetically determined serum urate levels in 339,256 unrelated White British indi-
viduals (54% female) in the UK Biobank who were aged 40–69 years (mean age, 56.87; SD,
7.99) when recruited from 2006 to 2010. Mendelian randomization (MR) analyses were per-
formed to replicate significant findings using various genome-wide association study
(GWAS) consortia data. Sensitivity analyses were conducted to examine possible pleiotropic
effects on metabolic traits of the genetic variants used as instruments for urate. PheWAS
analysis, examining the association with 1,431 disease outcomes, identified 13 distinct phe-
codes representing 4 disease groups (inflammatory polyarthropathies, hypertensive disease,
circulatory disease, and metabolic disorders) and 9 disease outcomes (gout, gouty arthropa-
thy, pyogenic arthritis, essential hypertension, coronary atherosclerosis, ischemic heart dis-
ease, chronic ischemic heart disease, myocardial infarction, and hypercholesterolemia) that
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were associated with genetically determined serum urate levels after multiple testing correc-
tion (p < 3.35 × 10−4). TreeWAS analysis, examining 10,750 ICD-10 diagnostic terms, identi-
fied more sub-phenotypes of cardiovascular and cerebrovascular diseases (e.g., angina
pectoris, heart failure, cerebral infarction). MR analysis successfully replicated the associa-
tion with gout, hypertension, heart diseases, and blood lipid levels but indicated the existence
of genetic pleiotropy. Sensitivity analyses support an inference that pleiotropic effects of
genetic variants on urate and metabolic traits contribute to the observational associations
with CVDs. The main limitations of this study relate to possible bias from pleiotropic effects of
the considered genetic variants and possible misclassification of cases for mild disease that
did not require hospitalization.
Conclusion
In this study, high serum urate levels were found to be associated with increased risk of dif-
ferent types of cardiac events. The finding of genetic pleiotropy indicates the existence of
common upstream pathological elements influencing both urate and metabolic traits, and
this may suggest new opportunities and challenges for developing drugs targeting a com-
mon mediator that would be beneficial for both the treatment of gout and the prevention of
cardiovascular comorbidities.
Author summary
Why was this study done?
• Serum urate level has been extensively studied in epidemiological studies in relation to
various diseases, but the extent of any causal effect is still unclear, making it difficult to
evaluate the clinical importance of urate.
• Mendelian randomization (MR) uses naturally occurring genetic variants as instru-
ments to infer the causal role of a risk factor in a disease or outcome of interest. Previous
MR studies were typically hypothesis driven, and few studies have comprehensively
investigated how serum urate level might influence overall health.
What did the researchers do and find?
• We implemented a phenome-wide association study (PheWAS) followed by a Bayesian
analysis of tree-structured phenotypic model (TreeWAS) and MR analyses to explore
the association between urate and a broad range of disease outcomes in the UK
Biobank.
• We identified gout, hypertension, hypercholesterolemia, and a multitude of cardiovas-
cular and cerebrovascular diseases (e.g., coronary atherosclerosis, myocardial infarction,
angina pectoris, ischemic heart disease, heart failure, and cerebral infarction) that were
associated with serum urate levels.
• MR analysis using various GWAS consortia data successfully replicated these associa-
tions but indicated the existence of genetic pleiotropy. Sensitivity analyses examining
A phenome-wide mendelian randomization study on serum urate levels
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the pleiotropic effects of urate genetic risk loci on a set of metabolic traits support an
inference that genetic pleiotropy contributes to observational association between urate
and different types of cardiac events.
What do these findings mean?
• There was little evidence of causality; instead, the pleiotropy of genetic variants on urate
and metabolic traits is indicated for the observed associations with cardiovascular/meta-
bolic diseases.
• The linked biological pathways between urate and metabolic traits indicated that the fre-
quent coexistence of gout with hypertension, cardiovascular diseases (CVDs), and
hyperlipidemia is a range of interrelated disease outcomes due to linked pathogenic
components, rather than isolated events.
• These findings support the European League against Rheumatism (EULAR) recommen-
dation of systematic screening and assessment of cardiovascular/metabolic comorbidi-
ties in gout patients.
• These findings may suggest new opportunities and challenges for developing drugs tar-
geting a more distal mediator that would be beneficial for both the treatment of gout
and the prevention of cardiovascular/metabolic comorbidities.
Introduction
The role of urate has been explored in a large number of observational studies in relation to a
multitude of health outcomes [1]. Apart from gout, compelling evidence exists for the associa-
tions between high serum urate level and an increased risk of non–crystal deposition disor-
ders, including hypertension, cardiovascular diseases (CVDs), and metabolic syndrome [2,3].
Although considerable research efforts have been made in trying to understand the pathologi-
cal role of urate in such disorders, its causal role has not been clearly established. Therefore, it
has been argued that either these associations are confounded by other risk factors, such as
obesity, or they represent reverse causality [4].
As is typical in complex traits, genetic determinants are implicated in the regulation of
serum urate levels. Genetic studies among twins and families have reported a substantial heri-
table component of serum urate level with an estimated heritability of 40%–60% [5,6]. The
genetic determinants of serum urate level have been explored in several genome-wide associa-
tion studies (GWASs) [7–10] and the wealth of resultant data allows for the identification and
application of genetic variants as instruments to help separate causal from noncausal associa-
tions, given that genotypes are generally independent of environmental exposures and the
transmission of genetic information is usually unidirectional. Investigating the associations
between genetic variants related to serum urate and disease outcomes might help provide
causal evidence in support of the hypotheses that link urate to multiple clinical disorders. Pre-
vious mendelian randomization (MR) studies using the genetic variants as instruments of
serum urate levels reported inconsistent findings [11–14]. While some supported a causal
effect on health outcomes beyond gout (e.g., diabetic macrovascular disease, CVD mortality,
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and sudden cardiac death), the majority reported no causal relationships [1]. Specifically, most
of the negative results of previous MR studies are perhaps due to the selection of genes selec-
tively involved in renal handling of urate, while a substantial portion of cardiovascular risk is
probably due to pleiotropic genes controlling for xanthine oxidase activity and urate
production.
Our recently published MR–phenome-wide association study (PheWAS) analysis on the
interim release data of UK Biobank (n = 120,091) provided an overview of the disease out-
comes that were associated with the urate genetic risk loci [15]. Our study demonstrated that
serum urate level shared the same genetic risk loci with multiple disease outcomes, particularly
those related to cardiovascular/metabolic diseases and autoimmune disorders [15]. These find-
ings provide a rationale for further investigating whether these cross-phenotype associations
are causal. Although we have applied multiple methodologies to distinguish the PheWAS asso-
ciations that were causal from those due to pleiotropy or genetic linkage, the use of the interim
release data of UK Biobank set power limitations to our investigation and did not allow us to
investigate less prevalent phenotypes. The release of the full UK Biobank GWAS genotype
dataset provides a unique opportunity to further explore the previous MR-PheWAS findings,
repeat analysis with the larger available cohort, and include phenotypes that were not investi-
gated in the previous study due to an insufficient number of cases.
In this study, we performed an updated phenome-wide mendelian randomization study
(PWMR) by using data from the full UK Biobank cohort. A weighted polygenic risk score
(GRS) incorporating effect estimates of multiple genetic risk loci taken from the most recent
and largest GWAS of serum urate was employed as a proxy of serum urate level [8]. The frame-
work of phenome was defined by using both the PheCODE schema (also used in the previous
MR-PheWAS) [15] and a novel Bayesian analysis framework, termed TreeWAS (tree-struc-
tured phenotypic model) [16]. Any replication of previous findings and/or novel findings was
further explored in this study.
Methods
This study is reported as per the STROBE guideline (S1 STROBE Checklist). UK Biobank has
ethics approval from the North West Multi-Centre Research Ethics Committee (11/NW/
0382). Appropriate informed consent was obtained from participants and ethical approval was
covered by the UK Biobank, from which data for this work were obtained (under approved
data request application ID 10775). Any additional ethical approval was adjudged unnecessary
for the present study. Although there is no formal or documented protocol for this study, the
main analyses of PheWAS, TreeWAS, and the replication study were prespecified; the sensitiv-
ity analysis for the GRS of genetic polymorphisms involved in renal handling of urate was sup-
plemented according to the reviewer’s comments to better interpret the findings.
UK Biobank
UK Biobank is a large-scale, population-based prospective cohort study, which recruited over
500,000 participants aged between 40 and 69 years in 2006–2010 and combined extensive mea-
surement of baseline data and genotype data with linked national medical records (e.g., inpa-
tient hospital episode records, cancer registry, and death registry) for longitudinal follow-up.
This study was constrained to a subset of unrelated White British individuals with high-quality
genotype data in order to minimize the influence of diverse population structure within UK
Biobank. Details about genotype data and phenotype data and the procedures of quality con-
trol are described in S1 Text.
A phenome-wide mendelian randomization study on serum urate levels
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Weighted genetic risk score
To generate a genetic proxy for serum urate, genetic variants associated with urate were
searched across the GWAS catalogue and literature. Thirty-one genetic variants associated
with urate among European populations were identified from previous GWASs [7,8] and were
selected as components of the genetic proxy for serum urate level. The overall proportion of
variance (adjusted R2) of urate explained by the 31 genetic variants was around 7% [8]. The
SNP effect on urate (effect size and standard error [SE]) was taken from the largest meta-analy-
sis of GWASs performed by the Global Urate Genetics Consortium (GUGC) [8]. A weighted
GRS was constructed by incorporating effect estimates of the 31 urate variants for UK Biobank
participants. Specifically, the GRS was created by adding up the number of urate-increasing
alleles for each SNP weighted for the SNP effect size on serum urate level (regression beta coef-
ficients) and then adding this weighted score for all 31 SNPs.
Phenome framework
We analyzed three phenotypic datasets (i.e., inpatient hospital records, cancer registry data,
and death registry data) available in the UK Biobank database. As we were interested in disease
phenotypes, the ontology of the phenome was defined based on the ICD codes in the electronic
medical records. We pooled the hospital episode data, cancer registry data, and death registry
data together and included both the primary and secondary ICD codes. Individual ICD codes
could not be directly used to define the phenome, as they represent specific sub-phenotypes of
a similar set of diseases, instead of independent phenotypes. To account for the correlations
between ICD codes, we applied two strategies: (i) the PheCODE schema that has been recently
updated and successfully adopted in our previous MR-PheWAS [15]; and (ii) a novel Bayesian
analysis of a TreeWAS that was developed by researchers from the Wellcome Trust Centre for
Human Genetics [16].
PheCODE schema. The PheCODE system was developed to combine one or more related
ICD codes into distinct disease groups [17]. To develop a phenotyping method applicable to
the ICD-10 coding system in UK Biobank, we created a map to match ICD-9/10 codes to phe-
codes [15]. The latest version of the PheCODE system includes 1,866 hierarchical phenotype
codes that could be directly matched to the ICD-9/10 codes and provides a scheme to automat-
ically exclude patients that have similar or potentially overlapping disease states from the cor-
responding control group (e.g., excluding type 1 diabetes from being in the control group
when analyzing the phenotype of type 2 diabetes). The PheCODE map is made publicly acces-
sible via the link https://phewascatalog.org/phecodes_icd10.
TreeWAS. A novel Bayesian analysis on a TreeWAS has recently been developed to inter-
rogate the increasingly specific sub-phenotypes defined by the ICD-10 coding system. It has
been suggested that this model has higher statistical power for detecting genotype-phenotype
associations [16]. In principle, this phenotyping method models the genetic coefficients across
all phenotypes as a set of random variables. To model the correlations of the hierarchical tree-
like structure of ICD-10 codes (termed as TreeWAS), a Markov process is applied to allow the
genetic coefficients to evolve down the tree trunk and branches. The tree structure is deter-
mined based on the classification hierarchy of the ICD-10 coding system, in which each node
in the tree represents a clinical term in the classification. More details about the tree-structured
phenotyping process are described elsewhere [16].
Statistical analysis
To take advantage of both phenotyping models, we explored the association between the
weighted GRS of urate and the phenome framework defined by both the PheCODE schema
A phenome-wide mendelian randomization study on serum urate levels
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(described as PheWAS analysis) and the tree-structured phenotypic model (described as Tree-
WAS analysis). The correlation with weighted GRS was examined for a number of potential
confounding factors including sex, age, body mass index (BMI), assessment center, and the
first 5 genetic principal components (PCs). In the PheWAS analysis, associations between
weighted GRS and phecodes (with no fewer than 20 cases) were examined by logistic regres-
sion. Given that phenotypes investigated are not totally independent in the PheCODE system,
because multiple levels of phenotypic granularity were used for the definition of the case-con-
trol groups, we applied the false discovery rate (FDR) method (corresponding to the FDR of
q< 0.05) to account for multiple comparisons instead of the more stringent Bonferroni cor-
rection [18]. In the TreeWAS analysis, associations between the weighted GRS and the phe-
nome variables were tested by the Bayesian network analysis at both terminal and internal
nodes of the tree structure. The marginal posterior probability (PP) for each node in the tree
(where its genetic coefficient was nonzero) and the corresponding maximum a posteriori
(MAP) effect estimate with 95% credible interval were determined by using the MAP estima-
tor. Any association with any node of the tree at the PP� 0.95 was reported for further investi-
gation. Details about the TreeWAS analysis have been described previously [16]. All the
statistical analyses were implemented by R 3.3.2.
Replication in MR-base database
To validate findings, PheWAS associations were further examined in the MR-base database
for replication in different populations [19,20]. We used this platform to make causal inference
by performing two-sample MR analysis using available GWAS consortia data. We applied the
simplest inverse variance weighted mendelian randomization (MR IVW) approach as crude
analysis; if there was horizontal pleiotropy that violated the assumptions of the MR IVW, we
applied a mixture-of-experts machine learning framework of mendelian randomization
(MR-MoE) to predict the performance of three main classes of MR analytical approaches
(mean-based, median-based, and mode-based methods) in the context of different models of
pleiotropy and then selected the most likely unbiased causal estimate for each specific circum-
stance [20]. Full details of these MR approaches, including their different assumptions, are
provided in S1 Text and S1 Table. The schematic presentation of the overall study design is
shown in Fig 1.
Sensitivity analyses
We created a separate GRS of seven genetic polymorphisms, which are involved in renal han-
dling of urate (six urate transporter-coding genes: SLC22A12, SLC2A9, ABCG2, SLC22A11,
SLC17A1, SLC16A9, and one urate transporter-related scaffolding gene, PDZK1), as a sensitiv-
ity analysis. We then performed additional sensitivity analyses to further explore any pleiotro-
pic associations. To identify genetic variants showing pleiotropy, we examined their
association with a set of metabolic traits (i.e., BMI, waist-to-hip ratio [WHR], total cholesterol
[TC], low-density lipoprotein cholesterol [LDL-c], high-density lipoprotein cholesterol [HDL-
c], fasting glucose, 2-hour glucose, glycoproteins, systolic blood pressure [SBP], and diastolic
blood pressure [DBP]) through publicly available resources from various GWAS consortia (a
summary of these GWASs is provided in S1 Text). An association was declared as pleiotropic
when these GWAS summary data reported any association between the serum urate risk loci
and these metabolic traits at p< 1.61 × 10−3 (the threshold was determined based on the Bon-
ferroni correction with a significance level of α = 0.05 divided by the number of 31 serum
urate risk loci analyzed in this study). These 31 urate genetic risk loci were then divided into
five categories, accordingly: (i) urate-specific loci, including 14 SNPs with no pleiotropic effect
A phenome-wide mendelian randomization study on serum urate levels
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on the examined metabolic traits (S2 Table); (ii) urate-obesity pleiotropic loci, including 10
SNPs with pleiotropic effects on BMI or WHR (S3 Table); (iii) urate-BP pleiotropic loci, includ-
ing 10 SNPs with pleiotropic effects on blood pressures (BPs) (i.e., DBP and SBP) (S4 Table);
(iv) urate-lipid pleiotropic loci, including 6 SNPs with pleiotropic effects on lipids (i.e., TC,
LDL-c, and HDL-c) (S5 Table); and (v) urate-glucose pleiotropic loci, including 3 SNPs with
pleiotropic effects on blood glucose (fasting glucose, 2-hour glucose, glycoproteins) (S6 Table).
A set of GRSs were created accordingly to recalculate the effect estimates in PheWAS analysis.
Results
We included 339,256 unrelated White British individuals from the full UK Biobank cohort,
consisting of 157,146 men and 182,110 women. The mean age of the study population was
Fig 1. Schematic representation of the study design. BP, blood pressure; CARDIoGRAMplusC4D, Coronary ARtery
DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease (C4D)
Genetics consortium; FDR, false discovery rate; GLGC, Global Lipids Genetic Consortium; GRS, polygenic risk score;
GUGC, Global Urate Genetic Consortium; GWAS, genome-wide association study; ICBP, International Consortium
for Blood Pressure; ISGC, Ischaemic stroke Genetic Consortium; MR IVW, inverse variance weighted mendelian
randomization; MR-MoE, a mixture-of-experts machine learning framework of mendelian randomization; PheWAS,
phenome-wide association study; PP, posterior probability; TreeWAS, tree-structured phenotypic model.
https://doi.org/10.1371/journal.pmed.1002937.g001
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56.87 (SD: 7.99) and the mean BMI was 27.40 (SD: 4.76) kg/m2 at the time of recruitment.
Other sociodemographic characteristics of the study population are summarized in S7 Table.
The mean value of weighted GRS among the study population was 0.44 (SD: 0.31), which is
equivalent to 0.44 mg/dL of serum urate level. The correlations between the weighted GRS and
potential confounding factors (i.e., age, sex, BMI, assessment center, and the PCs) are provided
in S7 Table. Of these, two variables (i.e., assessment center and the PCs) were statistically sig-
nificantly correlated with the weighted GRS and therefore were adjusted as covariates.
PheWAS and TreeWAS associations
Within the study population, we identified 10,750 unique ICD-10 codes and 3,113 ICD-9
codes in total. After mapping the diagnostic ICD-10/9 codes in UK Biobank to phecodes, the
phenome defined by PheCODE schema consisted of 1,853 distinct phecodes among the study
population. After filtering out the phecodes with less than 20 cases, PheWAS analysis was per-
formed for 1,431 phecodes (median number of cases: 345 [range, 20–107,298]) that could be
classified into 17 broadly related disease categories (Table 1). Associations with the weighted
GRS of urate were examined for 1,431 case-control groups, leading to an adjusted significance
threshold of p< 3.35 × 10−4 (corresponding to the FDR of q< 0.05) to account for multiple
testing. The derived summary PheWAS data are provided in S1 Data. Of these, 13 phecodes
were identified to be associated with genetically determined high serum urate level at
p< 3.35 × 10−4 (Table 2). These phecodes represent 4 disease groups: inflammatory polyar-
thropathies (p = 4.97 × 10−19), hypertensive disease (p = 6.02 × 10−7), circulatory disease
(p = 3.29 × 10−4), and metabolic disorders (p = 3.33 × 10−4); and 9 disease outcomes: gout
(p = 4.27 × 10−123), gouty arthropathy (p = 1.39 × 10−5), pyogenic arthritis (p = 2.87 × 10−4),
essential hypertension (p = 6.26 × 10−7), coronary atherosclerosis (p = 1.17 × 10−5), ischemic
heart disease (p = 1.73 × 10−5), chronic ischaemic heart disease (p = 1.52 × 10−5), myocardial
infarction (p = 5.23 × 10−5), and hypercholesterolemia (p = 3.34 × 10−4).
In the Bayesian analysis framework, containing 10,750 diagnostic terms, a total of 27 par-
ent/child nodes of ICD-10 terms were identified with PP� 0.95. They were clustered mainly
in five branches of the hierarchical tree structure (Fig 2 and S8 Table): (i) block M10: gout
(PP = 1.00) and its sub-phenotypes M10.0 (idiopathic gout) and M10.9 (gout, unspecified); (ii)
block I10-I15: hypertensive disease (PP > 0.99) and its sub-phenotype I10 (essential hyperten-
sion); (iii) block I20-I25: ischemic heart diseases (PP > 0.99), and its sub-phenotypes: I20
(angina pectoris), I21 (acute myocardial infarction), I25 (chronic ischemic heart disease), I25.1
(atherosclerotic heart disease), and I25.2 (old myocardial infarction); (iv) block I30-I52: other
forms of heart disease (PP > 0.99), and its sub-phenotypes I50 (heart failure) and I50.1 (left
ventricular failure); and (v) block I60-I69: cerebrovascular diseases (PP > 0.99), and its sub-
phenotype I10 (cerebral infarction).
Findings from PheWAS and TreeWAS were generally consistent in their associations with
gout, hypertensive disease, and heart diseases, while a number of additional sub-phenotypes
were identified by TreeWAS. Association with the disease group of inflammatory polyarthro-
pathies was statistically significant in PheWAS (OR = 1.27, 95% CI: 1.21–1.34,
p = 4.97 × 10−19) but had a moderate PP in TreeWAS (OR = 1.07, 95% CI: 1.06–1.08,
PP = 0.76). We examined the specific diseases included in this disease group (M05-M06: rheu-
matoid arthritis [RA], M07: psoriatic and enteropathic arthropathies, M08-09: juvenile arthri-
tis, M10: gout, and M11-14: arthropathies and other arthritis), and only gout had a significant
association in PheWAS analysis. Association with cerebrovascular diseases had a high PP in
TreeWAS (OR = 1.07, 95% CI: 1.06–1.08, PP> 0.99) but did not reach the significance thresh-
old of PheWAS (OR = 1.08, 95% CI: 0.99–1.16, p = 0.070), although their estimates were of the
A phenome-wide mendelian randomization study on serum urate levels
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same direction. We recalculated the PheWAS estimates by adding up self-reported stroke
cases to increase statistical power, but the corresponding estimates were still not statistically
significant (OR = 1.05, 95% CI: 0.99–1.13, p = 0.130).
Replication in MR-base database
To validate the findings, we performed two-sample MR analyses on associated diseases (i.e.,
gout, RA, coronary heart disease [CHD], myocardial infarction, ischemic stroke) or on their
corresponding intermediate traits or surrogate outcomes (i.e., SBP, DBP, TC, LDL-c, HDL-c)
(Table 3). Results from MR IVW suggested that a genetically determined high serum urate
Table 1. The number of phenotypes and cases in each disease category.
Disease categories Number of phenotypes Number of cases
Minimum Mean Maximum
Circulatory diseases 140 434 3,581 107,298
Congenital anomalies 45 102 230 1,480
Dermatological diseases 74 283 2,544 89,976
Diseases in sense organs 104 253 1,228 31,845
Digestive diseases 143 551 3,123 62,862
Neoplasms 129 493 2,558 84,098
Infectious diseases 48 190 958 8,600
Endocrine and metabolic diseases 103 154 1,590 35,954
Hematopoietic diseases 40 228 1,200 10,095
Neurological diseases 69 224 1,180 32,194
Respiratory diseases 71 674 2,448 49,782
Mental disorders 64 260 1,493 23,226
Genitourinary diseases 140 655 2,536 82,964
Pregnancy complications 28 237 914 7,518
Musculoskeletal diseases 109 347 2,847 59,852
Clinical symptoms 27 711 3,741 33,553
Injuries and poisonings 97 388 1,079 13,303
https://doi.org/10.1371/journal.pmed.1002937.t001
Table 2. Disease outcomes associated with the weighted GRS of urate in PheWAS analysis.
Phecode Disease outcomes n_cases n_controls beta SE OR (95% CI) p-value
274.1 Gout 2,532 335,108 1.682 0.071 5.37 (4.67–6.18) 4.27 × 10−123
714 Inflammatory polyarthropathies 15,408 320,862 0.244 0.027 1.27 (1.21–1.34) 4.97 × 10−19
401 Hypertension 63,694 274,477 0.076 0.015 1.07 (1.05–1.11) 6.02 × 10−7
401.1 Essential hypertension 63,442 274,477 0.077 0.015 1.08 (1.05–1.11) 6.26 × 10−7
411.4 Coronary atherosclerosis 25,795 311,554 0.096 0.022 1.10 (1.05–1.14) 1.17 × 10−5
274.11 Gouty arthropathy 88 335,108 1.631 0.375 5.10 (2.45–10.66) 1.39 × 10−5
411.8 Chronic ischemic heart disease 25,567 311,554 0.095 0.022 1.09 (1.05–1.14) 1.52 × 10−5
411 Ischemic heart disease 25,617 311,554 0.094 0.022 1.09 (1.05–1.14) 1.73 × 10−5
411.2 Myocardial infarction 9,829 311,554 0.138 0.034 1.14 (1.07–1.22) 5.23 × 10−5
711.1 Pyogenic arthritis 270 277,590 0.742 0.205 2.10 (1.41–3.13) 2.87 × 10−4
459.9 Circulatory disease 107,298 230,622 0.046 0.013 1.04 (1.02–1.07) 3.29 × 10−4
277 Metabolic disorders 35,954 302,209 0.067 0.019 1.07 (1.03–1.11) 3.33 × 10−4
272.11 Hypercholesterolemia 27,040 308,948 0.077 0.021 1.08 (1.04–1.12) 3.34 × 10−4
Abbreviations: GRS, polygenic risk score; PheWAS, phenome-wide association study
https://doi.org/10.1371/journal.pmed.1002937.t002
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level was associated with increased risk of gout (OR = 4.53, 95% CI: 3.64–5.64; peffect =
9.66 × 10−42), DBP (OR = 1.04, 95% CI: 1.02–1.08; peffect = 0.044), SBP (OR = 1.03, 95% CI:
1.00–1.06; peffect = 0.050), CHD (OR = 1.10, 95% CI: 1.02–1.19; peffect = 0.014), myocardial
infarction (OR = 1.11, 95% CI: 1.02–1.20; peffect = 0.017), and decreased level of HDL-c
(OR = 0.93, 95% CI: 0.88–0.98; peffect = 0.007) but had no effect on ischemic stroke (OR = 1.03,
95% CI: 0.93–1.14; peffect = 0.582). A test for directional horizontal pleiotropy indicated the
existence of pleiotropy on the causal estimates of DBP (ppleiotropy = 0.014), SBP (ppleiotropy =
0.003), CHD (ppleiotropy = 0.008), myocardial infarction (ppleiotropy = 0.008), and HDL-c (ppleio-
tropy = 0.016), indicating the MR IVW estimates are likely biased. Using the MR-MoE analysis
to select the most appropriate MR approach to deal with different models of pleiotropy, we
derived a statistically significant causal estimate only for gout (OR = 4.50, 95% CI: 3.62–5.59,
peffect = 3.35 × 10−77) (Table 3). Causal estimates from each of the MR analytical approaches are
provided in S9–S17 Tables.
Fig 2. A hierarchical structure of disease outcomes associated with urate in TreeWAS analysis. TreeWAS, tree-
structured phenotypic model.
https://doi.org/10.1371/journal.pmed.1002937.g002
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Table 3. Replication of MR effect estimates in MR-base database.
Outcome beta SE OR (95% CI) peffect ppleiotropy� n_cases n_total Data source
Replication of significant PheWAS associations
Gout
PheWAS 1.682 0.071 5.37 (4.67−6.18) 4.27 × 10−123 - - 2,532 337,640 UKBB
MR IVW 1.511 0.112 4.53 (3.64−5.64) 9.66 × 10−42 0.485 2,115 67,259 GUGC
MR-MoE 1.504 0.081 4.50 (3.62−5.59) 3.35 × 10−77 - -
Hypertension
PheWAS 0.076 0.015 1.07 (1.05−1.11) 6.02 × 10−7 - - 63,694 338,171 UKBB
DBP
MR IVW 0.042 0.020 1.04 (1.02−1.08) 0.044 0.014 - - 69,395 ICBP
MR-MoE 0.034 0.019 1.03 (0.99−1.07) 0.084 - - - -
SBP
MR IVW 0.031 0.015 1.03 (1.00−1.06) 0.050 0.003 - - 69 395 ICBP
MR-MoE 0.008 0.007 1.01 (0.99−1.02) 0.266 - - - -
CHD
PheWAS 0.094 0.022 1.09 (1.05−1.14) 1.73 × 10−5 - - 25,617 337,171 UKBB
MR IVW 0.098 0.038 1.10 (1.02−1.19) 0.014 0.008 60,801 123,504 CARDIoGRAMplusC4D
MR-MoE 0.047 0.028 1.05 (0.99−1.10) 0.086 - -
Myocardial infarction
PheWAS 0.138 0.034 1.14 (1.07−1.22) 5.23 × 10−5 - - 9,829 321,383 UKBB
MR IVW 0.105 0.041 1.11 (1.02−1.20) 0.017 0.008 43,676 128,199 CARDIoGRAMplusC4D
MR-MoE 0.058 0.030 1.06 (0.99−1.12) 0.055 - -
Hypercholesterolemia
PheWAS 0.077 0.021 1.08 (1.04−1.12) 3.34 × 10−4 - - 27,040 335,988 UKBB
TC
MR IVW 0.028 0.036 1.03 (0.96−1.10) 0.440 0.602 - - 173,082 GLGC
MR-MoE 0.005 0.026 1.00 (0.95−1.06) 0.848 - -
HDL-c
MR IVW -0.075 0.026 0.93 (0.88−0.98) 0.007 0.016 - - 187,167 GLGC
MR-MoE -0.030 0.015 0.97 (0.94−1.01) 0.058 - -
LDL-c
MR IVW 0.011 0.023 1.05 (0.95−1.16) 0.627 0.175 - - 187,365 GLGC
MR-MoE 0.011 0.023 1.05 (0.95−1.16) 0.627 - -
Replication of additional TreeWAS associations
Ischemic stroke
PheWAS 0.071 0.040 1.08 (0.99−1.16) 0.070 - - 9,528 338,172 UKBB
MR IVW 0.029 0.052 1.03 (0.93−1.14) 0.586 0.290 10,307 19,326 ISGC
MR-MoE 0.029 0.052 1.03 (0.93−1.14) 0.586 - -
�Test for directional horizontal pleiotropy.
Abbreviations: CARDIoGRAMplusC4D, Coronary ARtery DIsease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery Disease
(C4D) Genetics consortium; CHD, coronary heart disease; DBP, diastolic blood pressure; GLGC, Global Lipids Genetics Consortium; GUGC, Global Urate Genetics
Consortium; HDL-c, high-density lipoprotein cholesterol; ICBP, International Consortium of Blood Pressure; ISGC, Ischaemic stroke Genetic Consortium; LDL-c, low-
density lipoprotein cholesterol; MR, mendelian randomization; MR IVW, inverse variance weighted mendelian randomization; MR-MoE, a mixture-of-experts machine
learning framework of mendelian randomization; PheWAS, phenome-wide association study; SBP, systolic blood pressure; TC, total cholesterol; TreeWAS, tree-
structured phenotypic model; UKBB, UK Biobank
https://doi.org/10.1371/journal.pmed.1002937.t003
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Sensitivity analyses
PheWAS analysis using the GRS of 7 SNPs involved in renal handling of urate showed signifi-
cant associations with gout (p = 3.04 × 10−91) and related diseases (e.g., inflammatory polyar-
thropathies, gouty arthropathy) after FDR correction. A GRS of the remaining 24 SNPs
(excluding genetic polymorphisms involved in renal handling of urate) showed significant
associations with gout, hypertension, hypercholesterolemia, and CVDs (e.g., coronary athero-
sclerosis, ischemic heart diseases, and myocardial infarction) (S18 Table). Given that most of
the related outcomes were CVDs, we performed further sensitivity analyses to examine the
potential of any pleiotropy effect of urate risk variants on metabolic traits. We recalculated the
PheWAS estimates by using a number of GRSs created based on their association with a set of
metabolic traits (Fig 3 and S19 Table), and the specific metabolic traits investigated were fur-
ther determined by the availability of summary GWAS data. The GRS of urate-specific loci
was only associated with gout and its upper disease group of inflammatory polyarthropathies,
but not with any cardiovascular/metabolic diseases. In contrast, the GRSs of pleiotropic loci
on obesity, BP, lipids, and glucose showed significant association with both gout and the
CVDs. Specifically, the GRS of pleiotropic loci on lipids was significantly associated with all
CVDs, including hypertensive diseases (i.e., essential hypertension), heart diseases (i.e., ische-
mic heart diseases), and metabolic disorders (i.e., hypercholesterolemia). Additionally, the
GRS of pleiotropic loci on glucose was significantly associated with diabetes (i.e., type 2 diabe-
tes). When removing any group of pleiotropic loci from the creation of GRS, their associations
with hypertensive diseases, heart diseases, and metabolic disorders were not statistically signifi-
cant (S20 Table). The effects of pleiotropic loci (mapped with genes) on serum urate level
against their effects on four representative disease outcomes were plotted in S1 Fig, in which
the two urate transporter genes (SLC2A9 and ABCG2) are recognised as the leading loci driv-
ing the association with gout, the GCKR gene is the leading locus driving the association with
hypercholesterolemia, and the PTPN11/ATXN2 gene is the leading locus driving the associa-
tion with hypertension and ischemic heart diseases.
Discussion
The present study demonstrated that genetically determined high serum urate level was consis-
tently associated with increased risk of several disease groups, including inflammatory polyar-
thropathies (e.g., gout and gouty arthropathy), hypertensive diseases (e.g., essential
hypertension), heart diseases (e.g., coronary atherosclerosis, myocardial infarction, angina
pectoris, ischemic heart disease, and heart failure), and metabolic disorders (e.g., hypercholes-
terolemia). This study, using data from the full UK Biobank cohort (n = 339,256), verified the
associations discovered in the previous MR-PheWAS study based on the interim release of UK
Biobank genetic data (n = 120,091) [15] and identified a number of new sub-phenotypes of dis-
eases (e.g., gouty arthropathy, angina pectoris, and heart failure). Some disease outcomes (e.g.,
disorders of iron metabolism, celiac disease) reported in the previous study were not identified
in the present study, as these associations were derived from the genetic linkage disequilibrium
between two single variants and therefore were diluted by the use of a weighted GRS of multi-
ple genetic instruments. Association between urate and the risk of gout, hypertension, CHD,
myocardial infarction, and a decreased level of HDL-c was successfully replicated in different
European populations by analyzing various GWAS consortia data documented in the MR-
base database [19], but a causal relationship was only supported for gout. Overall, findings
from the current study support the observational associations between high serum urate level
and increased risk of hypertensive diseases, heart diseases, and metabolic disorders and also
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indicated that these associations were more likely due to genetic pleiotropy instead of
causality.
A recent umbrella review summarized the published MR studies and examined the causal
relationship of serum urate level with a wide range of health outcomes, including gout, cardio-
vascular, metabolic, and neurocognitive disorders, and for the majority of investigated traits,
causality was not verified [1]. There were nine disease outcomes (e.g., diabetic macrovascular
disease, arterial stiffness [internal diameter of carotid artery], adverse renal events, Parkinson
disease, lifetime anxiety disorders, memory performance, CVD mortality, sudden cardiac
Fig 3. Network plot of the sensitivity analyses of PheWAS using different sets of weighted GRS. The red circles
represent the disease outcomes associated with the weighted GRS of the 31 urate genetic rick loci; the blue circles represent
disease outcomes associated with the weighted GRS of urate-specific risk loci; the green circles represent diseases outcomes
associated with urate-obesity pleiotropic loci; the orange circles represent disease outcomes associated with urate-lipid
pleiotropic loci; and the pink circles represent disease outcomes associated with urate-lipid pleiotropic loci. E70-E90,
metabolic disorders; GRS, genetic risk score; I10-I15, hypertensive diseases; I20-I25, ischemic heart diseases; M05-M14,
inflammatory polyarthropathies; PheWAS, phenome-wide association study.
https://doi.org/10.1371/journal.pmed.1002937.g003
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death, and gout) reported to have a nominally statistically significant causal relationship with
urate, but most of them presented with discordant results between MR studies or suffered
from methodological limitations (e.g., inadequate study power, invalid genetic instruments),
and only that for gout was verified based on convincing evidence.
Specifically, our finding that genetically predicted serum urate level is causally associated
with increased risk of gout is not surprising, as it is well known that the causal factor of gout is
represented by the monosodium urate crystals (MSUs), which leads to acute local inflamma-
tion in joints. Moreover, this study also detected an association between urate and the disease
group of inflammatory polyarthropathies. To investigate if there were any other types of
inflammatory polyarthropathies (beyond gout) associated with urate, we examined the associa-
tion of urate with all specific diseases included in this group, but none of them were statistically
significant. When excluding gout from this disease group, the association was not statistically
significant any longer, indicating the observed association was actually driven by gout.
Numerous epidemiological studies have reported that elevated serum urate level is related
to increased risk of hypertension, and their relationship has been consistent, showing a dose-
response relationship of similar magnitude [21]. Findings from our current study support this
association, but the magnitude of estimated effect size (OR = 1.07, 95% CI: 1.05–1.11) is
smaller than that of traditional epidemiological studies [22]. In our PheWAS, TreeWAS, and
MR IVW analysis, we consistently showed a moderate association between urate and different
types of heart disease, including coronary atherosclerosis, angina pectoris, ischemic heart dis-
eases, acute/old myocardial infarction, and heart failure; however, the MR-MoE analysis did
not support the causal inference after accounting for the presence of pleiotropy.
Large epidemiological studies have established an association between high serum urate
level and the increased risk of metabolic disorders [23]. The NHANES III survey study sug-
gested that a high serum urate level was associated with increased levels of serum LDL-c, tri-
glycerides, TC, and apolipoprotein-B and a decreased level of HDL-c [24]. Our study further
strengthened this epidemiological evidence and highlighted an association between urate and
hypercholesterolemia. Our MR IVW analysis replicated the corresponding association with its
surrogate outcome (i.e., HDL-c) but suggested the presence of pleiotropy instead of causality.
Additionally, epidemiological studies have also indicated that high serum urate level is associ-
ated with increased risk of diabetes [25]. However, this association was not detected in the
main PheWAS or TreeWAS analysis, while sensitivity analysis using the GRS of urate-glucose
pleiotropic loci (i.e., GCKR, IGF1R, and SLC16A9) identified significant association with type
2 diabetes.
To explore how genetic pleiotropy influences the association with cardiovascular/metabolic
diseases, we analysed all 31 urate loci across a set of metabolic traits and identified 14 SNPs
(urate-specific loci) that were exclusively associated with urate and 17 SNPs (pleiotropic loci)
that were associated with metabolic traits. When examining the urate-specific loci, their GRSs
were only associated with gout and its upper disease group of inflammatory polyarthropathies,
but not with any cardiovascular or metabolic diseases. In contrast, when categorizing the pleio-
tropic loci into different groups (e.g., GRS of urate-obesity loci, GRS of urate-BP loci, GRS of
urate-lipid loci, and GRS of urate-glucose loci), the GRSs of pleiotropic loci showed consistent
associations with both gout and the cardiovascular/metabolic diseases. When removing any
group of pleiotropic loci from the creation of GRS (e.g., GRS of urate without pleiotropic loci
on BP, or GRS of urate without pleiotropic loci on lipids), their association with heart diseases
and metabolic disorders was not statistically significant. Based on these findings, our study
suggests that the association between urate and CVDs is probably due to the pleiotropic effects
of genetic variants on urate and metabolic traits.
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Examining the associations between individual urate genetic risk loci and the related disease
outcomes highlighted two loci, GCKR and PTPN11/ATXN2, which drive their association with
hypercholesterolemia, hypertension, and ischemic heart disease. Pathway network analysis of
the leading pleotropic genes provides some clues on how genetic pleiotropy contributes to the
association between urate and cardiovascular/metabolic disease. Genetic variation in GCKR is
shown to be associated with concentrations of urate, triglyceride, and glucose [26]. The most
plausible explanation for this observation is that GCKR affects both serum urate and triglycer-
ide and glucose levels by a common unconfirmed mediator, which is proposed to be glucose-
6-phosphate [27]. The GCKR controls the hepatic production of glucose-6-phosphate, which is
catabolized for triglyceride synthesis via glycolysis, pyruvate, and acetyl coenzyme A, while glu-
cose-6-phosphate is also a precursor of purine (uric acid) metabolism [27]. Additionally, gene
functional annotation of PTPN11/ATXN2 highlights another subnetwork around hemostasis
pathways, including platelet activation, aggregation, and sensitization (activated by LDL-c)
[28], and these may be relevant to the observed association with hypertension and heart dis-
eases; but how this gene influences serum urate level has not yet been clearly demonstrated.
The detection of a multitude of cross-phenotype associations in this study adds to our
understanding of the extent of shared genetic/biological components between urate and meta-
bolic traits. Further characterizing the associations between urate and disease outcomes as
causal or pleiotropic contributes to our knowledge of how the role of urate should be inter-
preted and used in clinical practice in the management of related disease conditions. Given
that the observational associations between urate and cardiometabolic diseases are more likely
due to pleiotropy rather than causality, our study supports the notion that urate could be a pre-
dictor but probably not a direct target for the development of compounds that could reduce
cardiovascular/metabolic disease risk. The linked biological pathways between urate and meta-
bolic traits indicated that the frequent coexistence of gout with hypertension, CVDs, and
hyperlipidemia is a range of interrelated disease outcomes due to linked pathogenic compo-
nents, rather than isolated events. This supports the European League against Rheumatism
(EULAR) recommendation of systematic screening and assessment of cardiovascular/meta-
bolic comorbidities in gout patients [29]. The classification of high serum urate levels due to
renal handling dysfunction or high urate production would improve the identification of gout
patients with higher risk of metabolic and CVD, and promote a more selective and effective
use of urate-lowering drugs. The finding of genetic pleiotropy indicates the existence of com-
mon upstream pathological elements influencing both urate and metabolic traits, and this may
suggest new opportunities and challenges for developing drugs targeting a common mediator
that would be beneficial for both the treatment of gout and the prevention of cardiovascular/
metabolic comorbidities. This study has focused on the detection of cross-phenotype associa-
tions and highlighted the importance of pleiotropy in the links of these complex diseases. We
have made efforts to try to understand the cross-phenotype association in the context of a plei-
otropy model, but functionally characterizing the underlying biological mechanisms remains a
challenge in this field and is worthy of further investigation.
The strengths of this study include its potential to examine a broad spectrum of disease out-
comes related to urate and to reflect the shared biological relevance among associated pheno-
types, given that previous MR studies were typically hypothesis driven and few studies have
comprehensively investigated how serum urate level might influence overall health. Compared
with the previous MR-PheWAS [15], the present study extends the prior findings by combin-
ing genetic risk loci of urate into a weighted GRS, exploring genetic pleiotropy on a set of met-
abolic traits systematically, investigating more disease outcomes, assessing their associations
with>3-fold more cases, examining consistency of findings across two different phenotyping
models to reduce the probability of false positive/negative findings due to factors related to the
A phenome-wide mendelian randomization study on serum urate levels
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002937 October 18, 2019 15 / 20
model, and replicating the findings by performing two-sample MR in different populations.
Our study demonstrated the performance of two phenotyping models by accounting for the
differences in the specificity and granularity of different phenome definitions and by charac-
terizing the phenotypic correlations among different levels of ICD hierarchy. TreeWAS is
shown to increase statistical power and can detect new associations missed by conventional
PheWAS [16]. One of the major accomplishments of this study together with the previous
MR-PheWAS has been the establishment of a framework or workflow for PheWAS [15]. We
believe this study would be an excellent starting point for researchers who plan to use the UK
Biobank resource to comprehensively interrogate the clinical significance of biomarkers. The
updated version of PheCODE schema used in this study is made available for researchers who
are interested in performing PheWAS in UK Biobank.
This study also has limitations. The causal inference in our study is limited by the common
difficulty of pleiotropy caused by the use of multiple genetic instruments. Although we have
performed sensitivity analyses by grouping the pleiotropic loci based on metabolic traits and
exploring their association separately, there is still a probability of undetected pleiotropy or the
possibility that the relatively weak causal effects of urate on diseases were concealed by the
strong pleotropic effects of the genetic variants on metabolic traits. Moreover, as most cases
were identified from the inpatient hospital records, this may have impaired the coverage of
case ascertainment, especially for the diseases that do not usually cause events for hospitaliza-
tion. The incorporation of self-reported data would improve this limitation, but it is also likely
to mistakenly include patients who do not have a true diagnosis and introduce information
bias. As UK Biobank is currently performing disease adjudication and processing linkages to
general practice records and outpatient data, a widely covered and accurately defined criteria
of case ascertainment for PheWAS study would be possible in the future.
Conclusions
Overall, when taking together the findings from PheWAS/TreeWAS, MR replication, and sen-
sitivity analyses, we conclude a robust association between urate and a group of diseases
including gout, hypertensive diseases, heart diseases, and metabolic disorders of lipids, but the
causal role of urate is only supported in gout. Our study indicates that the association between
urate and CVDs is probably due to the pleiotropic effects of genetic variants on urate and met-
abolic traits. These findings support that urate could be a good predictor for the cardiovascu-
lar/metabolic disease risk. Further investigation on therapies targeting the shared biological
pathways between urate and metabolic traits would be beneficial for the treatment of gout and
the primary prevention of cardiovascular/metabolic comorbidities.
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